Canadian company develops new screening methods for psychedelic mushroom compounds

“In working with regulators, we look forward to establishing tools to create a stronger base of analytical methods for psychedelic compounds and products.”

Content of the article

Vancouver-based Numinus Wellness has announced the development of proprietary methods to test and screen for psychedelic mushroom compounds.

Content of the article

“The tests we have developed and validated at Numinus Bioscience will facilitate the safety and efficacy testing of psychedelics for our products, our customers and strategic partners and, ultimately, the industry,” says Sharan sidhu , the scientific manager and general manager of the company.

“By working with regulators, we look forward to establishing tools to create a stronger base of analytical methods for psychedelic compounds and products,” adds Sidhu.

Earlier this year, Numinus partnered with Optimi Health, a mushroom brand focused on the health and wellness markets, on an information package that was sent to Health Canada. The packaging included the chemical constituents of an investigational product, information on the genotype and formulation, as well as procedures and processes for producing a constant dosage from psilocybe fungi.

The company completed its first legal harvest of psilocybe mushrooms last October.

“Now we can advance in the research and development of standardized cultivation, extraction and testing methods, and explore product formulations to support safe, evidence-based, accessible psychedelic-assisted psychotherapy, as well as create a sequenced spore library, ”Michael Tan, the company’s chief operating officer at the time said.

Content of the article

To subscribe to Weekend dispensary , a new weekly newsletter from The GrowthOp.